Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

112
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
112
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

75
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
75
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

78
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
78
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

112
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
112
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

63
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
63
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Information and vaccine hesitancy: The role of broadband Internet.

Health economics·2024
Same author

Recent Developments at DG Competition: 2019/2020.

Review of industrial organization·2020
Same author

Parallel imports, price controls, and innovation.

Journal of health economics·2019
Same author

Recent Developments at DG Competition: 2017/2018.

Review of industrial organization·2018
Same author

Recent Developments at DG Competition: 2016/2017.

Review of industrial organization·2017
Same author

Compulsory licensing and access to drugs.

The European journal of health economics : HEPAC : health economics in prevention and care·2014

Related Experiment Video

Updated: Nov 17, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.3K

Mergers with Differentiated Products: Where Do We Stand?

Tommaso Valletti1, Hans Zenger2

  • 1Imperial College Business School, Imperial College London, South Kensington Campus, London, SW7 2AZ U.K.

Review of Industrial Organization
|February 15, 2021
PubMed
Summary

This article reviews economic analysis of unilateral effects in mergers with differentiated products, focusing on competition and market share calibration. It offers insights for merger enforcement and understanding market dynamics.

Keywords:
Differentiated productsMergersUnilateral effects

More Related Videos

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
07:13

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities

Published on: October 27, 2023

1.5K
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

36.6K

Related Experiment Videos

Last Updated: Nov 17, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.3K
Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities
07:13

Author Spotlight: An Efficient and Robust Software for Automated Fusion of Multiple Preclinical Imaging Modalities

Published on: October 27, 2023

1.5K
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

36.6K

Area of Science:

  • Economics
  • Antitrust Law
  • Industrial Organization

Background:

  • The 2010 U.S. Horizontal Merger Guidelines are celebrating their 10th anniversary.
  • Merger enforcement, particularly in Europe, provides valuable experience.
  • Differentiated products present unique challenges in merger analysis.

Purpose of the Study:

  • To provide an overview of the current state of economic analysis for unilateral effects in mergers involving differentiated products.
  • To discuss the calibration of competitive effects in merger reviews.
  • To examine the role of market shares and structural presumptions in these markets.

Main Methods:

  • Review of economic literature on unilateral effects.
  • Analysis of merger enforcement experiences, especially in Europe.
  • Discussion of static and dynamic competition models.

Main Results:

  • Economic analysis of unilateral effects in differentiated product markets is evolving.
  • Calibration of competitive effects requires careful consideration of static and dynamic factors.
  • Market shares and structural presumptions play a nuanced role in differentiated product markets.

Conclusions:

  • The analysis of unilateral effects in differentiated product mergers is complex.
  • A deeper understanding of competition dynamics is crucial for effective merger enforcement.
  • Future research should continue to refine methods for assessing competitive impact.